Facebook
Twitter
Telegram
Report an ErrorRAPT Therapeutics Balance Sheet 2011-2024 | RAPT
Annual Balance Sheet RAPT Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-40.6 M | -30 M | - | -24.9 M | -77.4 M | -63.8 M | -47.5 M | - | - | - | - | - | - |
Long Term Debt |
4.46 M | 6.82 M | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
2.45 M | 2.17 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 2.22 M | 969 K | 110 M | - | - | - | - | - | - |
Total Current Liabilities |
21.8 M | 14.2 M | 9.6 M | 11.7 M | 9.26 M | - | - | - | - | - | - | - | - |
Total Liabilities |
26.3 M | 21 M | 12.3 M | 14.8 M | 11.5 M | 5.61 M | 113 M | - | - | - | - | - | - |
Deferred Revenue |
- | - | 1.02 M | 4.1 M | 4 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-485 M | -368 M | -284 M | - | -162 M | -119 M | -82.8 M | - | - | - | - | - | - |
Total Assets |
173 M | 266 M | 199 M | 119 M | 84.6 M | 69.6 M | 50.4 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
47.5 M | 38.9 M | 24 M | 24.9 M | 77.4 M | - | - | - | - | - | - | - | - |
Book Value |
147 M | 245 M | 186 M | 104 M | 73.1 M | 64 M | -62.4 M | - | - | - | - | - | - |
Total Shareholders Equity |
147 M | 245 M | 186 M | 104 M | 73.1 M | -97.1 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet RAPT Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
5.07 M | 5.66 M | 6.25 M | 6.82 M | 6.32 M | 6.72 M | 7.11 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
26.9 M | 21.1 M | 27.9 M | 21 M | 20.2 M | 19.9 M | 19.7 M | 12.3 M | 15.6 M | 13.5 M | 14.3 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 11.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | 645 K | 1.02 M | 1.54 M | 2.28 M | 3.14 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4 M | 4 M | 4 M | 4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-454 M | -422 M | -397 M | -368 M | -345 M | -324 M | -305 M | -284 M | -266 M | -247 M | -231 M | -215 M | -215 M | -215 M | -215 M | -162 M | -162 M | -162 M | -162 M | -119 M | -119 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
200 M | 221 M | 248 M | 266 M | 209 M | 222 M | 188 M | 199 M | 217 M | 231 M | 106 M | 119 M | 119 M | 119 M | 119 M | 84.6 M | 84.6 M | 84.6 M | 84.6 M | 69.6 M | 69.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
54.1 M | 50.2 M | 45.8 M | 38.9 M | 27.7 M | 57.2 M | 32.4 M | 24 M | 60 M | 86.2 M | 24.7 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 77.4 M | 77.4 M | 77.4 M | 77.4 M | 63.8 M | 63.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
173 M | 200 M | 220 M | 245 M | 189 M | 202 M | 168 M | 186 M | 202 M | 218 M | 91.6 M | 104 M | 104 M | 104 M | 104 M | 73.1 M | 84.6 M | 84.6 M | 84.6 M | 69.6 M | 69.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
173 M | 200 M | 220 M | 245 M | 189 M | 202 M | 168 M | 186 M | 202 M | 218 M | 91.6 M | 104 M | 104 M | 104 M | 104 M | 73.1 M | 73.1 M | 73.1 M | 73.1 M | -97.1 M | -97.1 M | -78.1 M | -70.2 M | -62.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency